FEATURED EDITORIAL
More about the "ARB MI paradox"
1 C-NET Research Group, LIGHT (Leeds Institute for Genetics Health and Therapeutics), Faculty of Medicine, University of Leeds, UK
2 Division of Cardiovascular Surgery, Saint Michaels Hospital and Division of Cardiology, North York General Hospital, Toronto, Canada
Correspondence to:
Correspondence to:
Professor A S Hall
C-NET Research Group, G Floor, Jubilee Wing, Great George Street, Leeds LS1 3EX, UK; a.s.hall{at}leeds.ac.uk
"Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease"
Abbreviations: ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; CV, cardiovascular; MI, myocardial infarction
Keywords: angiotensin; antagonist; infarction; myocardial; receptor
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Turley, A. J., Roberts, A. P., Morley, R., Thornley, A. R., Owens, W. A., de Belder, M. A.
(2008). Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up. ICVTS
7: 231-234
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
